Metabolic inhibitors have been used in oncology for decades, dating back to antimetabolites
developed in the 1940s. In the past 25 years, there has been increased recognition of …

Chronic proliferation is a major hallmark of tumor cells. Rapidly proliferating cancer cells are
highly dependent on nutrients in order to duplicate their cell mass during each cell division …

Cancer cells are metabolically vigorous and are superior in the uptake of nutrients and in the
release of the tumor microenvironment (TME)-specific metabolites. They create an acidic …

The L-type amino acid transporter 1 (LAT1 or SLC7A5) transports large neutral amino acids
across the membrane and is crucial for brain drug delivery and tumor growth. LAT1 forms a …

Amino acids are indispensable nutrients for both normal and cancer cells. Cancer cells are
unable to synthesize essential amino acids as well as some non‐essential amino acids …

Background Tumor angiogenesis is regarded as a rational anti-cancer target. The efficacy
and indications of anti-angiogenic therapies in clinical practice, however, are relatively …

L‐type amino acid transporter 1 (LAT1; SLC7A5), which preferentially transports large
neutral amino acids, is highly upregulated in various cancers. LAT1 supplies cancer cells …

Advances in cell metabolism over the past few decades have demonstrated glutamine as an
essential nutrient for cancer cell survival and proliferation. Glutamine offers a remarkable …

Poor selectivity, potential systemic toxicity and drug resistance are the main challenges
associated with chemotherapeutic drugs. MCT1 and MCT4 and LAT1 play vital roles in …

Although 4-borono-l-phenylalanine (4-BPA) is currently the only marketed agent available
for boron neutron capture therapy (BNCT), its low water solubility raises concerns. In this …